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BACKGROUND. Breast carcinoma survival rates were found to be higher in the U.S.
than in Europe.
METHODS. Multiple regression analysis of breast carcinoma survival rates among
women diagnosed between 1990 and 1992 was performed using clinical data from
population-based case series from the Surveillance, Epidemiogy, and End Results
(SEER) program (13,172 women) and the European Concerted Action on survival
and Care of Cancer Patients (EUROCARE) project (4478 women).
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RESULTS. Early-stage tumors (T1N0M0) were more frequent in the SEER data (41%
of cases) than in the EUROCARE data (29%). In the SEER data, early tumors were
more frequent in women age  65 years (43%) than in younger women (38%),
whereas the reverse was true in the European data (25% vs. 31%). In both case
series,  90% of women underwent surgery and 81–82% underwent lymphade-
nectomy, but the number of axillary lymph nodes evaluated was higher in the SEER
data than in the EUROCARE data. The 5-year survival rate was higher in the U.S.
case series (89%) than in the European series (79%). This differential was observed
for each stage category evaluated: early (T1N0M0), large lymph node-negative
(T2–3N0M0), lymph node-positive (T1–3NM0), locally advanced (T4M0), and
metastatic (M1) tumors. The overall relative excess risk (RER) of death was signif-
icantly higher (RER, 1.37; 95% conﬁdence interval [95% CI], 1.25–1.50) among
European women compared with U.S. women (referent group). Adjustment for
stage, age, surgery, and the number of lymph nodes evaluated explained most of
the excess risk (RER, 1.07; 95% CI, 0.98–1.17).
CONCLUSIONS. Transatlantic differences in the 5-year survival rates for women
diagnosed with breast carcinoma between 1990 and 1992 were attributable mainly
to differences in stage of disease. Resources should be invested to achieve earlier
diagnosis of breast carcinoma in Europe, especially for elderly women.Cancer
2004;100:715–22. © 2003 American Cancer Society.
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Breast carcinoma survival comparisons betweenthe European Concerted Action on Survival and
Care of Cancer Patients (EUROCARE) project and the
Surveillance, Epidemiology, and End Results (SEER)
program in the U.S. have demonstrated higher sur-
vival rates for U.S. women compared with European
women, particularly among elderly women.1 Interna-
tional differences in breast carcinoma survival rates in
Europe are also large.2–4
These differences are not easy to interpret. Longer
survival in one country versus another may be due to
the availability of better treatment, to similar treat-
ments being more effective because diagnosis is made
at an earlier stage of disease, or simply to early diag-
nosis without any advantage to the patient (lead-time
bias). Some of the survival differences between Europe
and the U.S. could, therefore, be artefactual. However,
actual survival differences could reﬂect different pat-
terns of care. Higher survival rates in the U.S. than in
Europe might also be attributable to a higher propor-
tion of tumors being diagnosed at an early stage as a
result of more intensive diagnostic activity.
When stage at diagnosis differs between countries
or regions, any survival differences should be at least
partly explained by appropriate stage-adjusted com-
parisons. However, disease stage depends on the
range and thoroughness of diagnostic procedures,
particularly those able to reveal occult metastases.5
Tumors classiﬁed as localized in an area where more
intensive diagnostic investigations are performed will,
on average, be more localized than tumors assigned to
that stage in an area where, for whatever reason, in-
vestigations are less thorough. The corollary is that the
survival of localized cases will be higher where inves-
tigations are thorough, not because of better treat-
ment but simply because of a different de facto deﬁ-
nition of stage at diagnosis. Advanced cases will also
have higher survival where investigations are more
thorough, because this group will include some early
metastatic cases that would be misclassiﬁed as local-
ized where investigations are less thorough. Therefore,
stage-adjusted survival comparisons should take ac-
count of the diagnostic examinations used to deter-
mine the stage of disease. A recent study using this
approach has shown that breast carcinoma survival
differences in Europe are mostly attributable to differ-
ences in disease stage at diagnosis.6
The objective of the current study was to improve
the interpretation of differences in breast carcinoma
survival between Europe and the U.S., by analyzing
the impact of disease stage, age, surgery, and the num-
ber of axillary lymph nodes evaluated after lymphad-
enectomy on survival, using data from the population-
based cancer registry networks contributing to
EUROCARE and SEER. The number of lymph nodes
evaluated pathologically was found to be one of the
most important determinants of the lymph node stage
of breast carcinoma during the early 1990s.7
MATERIALS AND METHODS
We used data from the EUROCARE High Resolution
study, in which detailed clinical information concern-
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ing stage, diagnostic examinations, and treatment was
collected for 4478 European women registered with
incident primary invasive breast carcinoma during
1990 in the territory of 17 population-based registries
in 6 countries: Estonia (national registry), France (Bas-
Rhin, Calvados, Coˆte d’Or, Doubs, He´rault, Ise`re,
Somme, and Tarn), Italy (Firenze, Modena, Ragusa,
and Varese), Spain (Granada), The Netherlands (Eind-
hoven), and the United Kingdom (Mersey and
Thames). Four registries included data for 816 women
diagnosed in 1991 and 47 women diagnosed in 1992
(19% of total). Details of the study design and sam-
pling have been published previously.4
We included all 13,172 cases of breast carcinoma
in U.S. women diagnosed in the SEER program areas
during 1990. Data regarding survival and the main
investigations and treatments were available in the
SEER public use data base.8 The following SEER reg-
istry areas were included: San Francisco-Oakland
SMSA, Connecticut, Detroit (Metropolitan), Hawaii,
Iowa, New Mexico, Seattle (Puget Sound), Utah, At-
lanta (Metropolitan).
Only invasive tumors in women ages 15–99 years
were included. Cases registered from a death certiﬁ-
cate only and those diagnosed at autopsy were ex-
cluded because their date of diagnosis and duration of
survival were unknown. The usual follow-up proce-
dures were adopted by each registry and  5 years of
follow-up for vital status were available for all cases.
Disease stage at diagnosis was deﬁned using TNM
characteristics.7 For women who underwent surgery,
pathologic T and N were used, whereas clinical infor-
mation on T, N, and M was used for the fraction of
women not treated surgically. Women were grouped
into ﬁve stage categories for survival analyses: early-
stage tumors (T1N0M0), large lymph node-negative
tumors (T2–3N0M0), lymph node-positive tumors
(T1–3NM0), locally advanced tumors (T4M0), and
metastatic tumors (M1). There also was a category for
tumors of an unknown stage.
Relative survival, expressing the probability of
cancer survival after adjustment for competing causes
of death, was estimated as the ratio of the observed
survival to the survival that would have been expected
if the women had been subject only to the age-speciﬁc
and sex-speciﬁc mortality rates observed in the gen-
eral population.9,10 Overall and stage-speciﬁc 5-year
relative survival rates were calculated by the Hakuli-
nen method11 using general population life tables for
women, speciﬁc for each European country or registry
territory. For the U.S., the national life table was used.
Differences in 5-year relative survival rates be-
tween Europe and the U.S. were modeled with a re-
cently developed multiple regression approach based
on generalized linear models and adopting the Pois-
son assumption for the observed number of deaths.12
The relative excess risks (RERs) derived from these
models quantify the extent to which the hazard of
death in a given region (e.g., age group) differs from
the hazard in the reference category (e.g., the U.S.),
after taking into account the background risk of death
in the general population of each country or region.
Age at diagnosis was categorized into 4 groups
( 40 years, 40–49 years, 50–69 years, and the refer-
ence group [age  70 years]). We used early-stage
tumors (T1N0M0) as the reference group for stage.
The probability of detecting axillary lymph node me-
tastases is reported to be positively correlated with the
number of lymph nodes evaluated pathologically. The
number of lymph nodes evaluated was included as a
determinant of lymph node status, categorized into
tertiles (1–9 lymph nodes evaluated [reference], 10–14
lymph nodes examined, and  15 lymph nodes exam-
ined), with a fourth category of women for whom
either the axilla was not evaluated surgically or this
information was not available. Surgery and radiother-
apy were categorized as yes, no, or no information
available, regardless of the type of surgery or type and
dose of radiotherapy (reference groups: women not
operated and not irradiated, respectively).
We modeled the effect on the RER for Europe,
compared with the U.S., of age and stage at diagnosis,
surgery, the number of evaluated lymph nodes, and
radiotherapy. We also tested three two-way interac-
tions: age and stage, follow-up (categorized into ﬁve
1-year intervals) and continent, and follow-up and
stage.
RESULTS
Breast carcinoma was diagnosed at a later stage in
Europe than in the U.S. (Table 1). Early-stage tumors
(T1N0M0) comprised 29% of all cases in the European
data and 41% in the U.S. data, whereas lymph node-
positive tumors were more frequent in Europe (31%)
than in the U.S. (24%). Other characteristics of the
case series include the percentages aged 70–99 (27%
of European cases and 33% of U.S. cases), those for
whom microscopic conﬁrmation of the diagnosis was
available (90% and 98%, respectively), or those for
whom follow-up information was unavailable (3.0%
and 2.2%, respectively).
Early-stage disease was more frequent among U.S.
women aged 70–99 (43%) than those aged 15–44 and
45–49 (29% and 36%, respectively), whereas the re-
verse was true in European women (24% vs. 29% and
33%, respectively). In both case series, large lymph
node-negative tumors (T2–3N0M0) comprised 17–21%
of all tumors among younger and older women, lymph
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node-positive tumors (T1–3NM0) were more fre-
quent among younger women, and advanced tumors
were more frequent among older women (Table 1).
Among women aged 70–99 who underwent sur-
gery, disparities in pathologic tumor size were
marked. The smallest tumors represented 3% of the
U.S. series and 1% of the European series (T1a,  5
mm in greatest dimension), with corresponding per-
centages of 16% and 6%, respectively, for T1b (6–10
mm in greatest dimension) and 35% and 31%, respec-
tively, for T1c (11–20 mm in greatest dimension) (data
not shown).
Most women were treated surgically (90% in
EUROCARE data, 97% in SEER data; Table 2). Lymph-
adenectomy was equally common in both series (81–
82%), but was more extensive in the U.S. than in
Europe. For example, approximately half of the U.S.
women (51%) had  15 lymph nodes evaluated, com-
pared with less than one-third of European women
(28%).
The overall 5-year relative survival rate was 89% in
the U.S. series and 79% in the European series (Fig. 1).
Survival was higher in the U.S. for each stage category,
except for women whose disease stage at diagnosis
was unknown. Survival was similar for early-stage tu-
mors (100% in the U.S. series and 97% in the European
series) but the difference increased with advancing
stage and was maximal for locally advanced tumors
(T4M0, 71% vs. 55%).
The age-adjusted RER of death was signiﬁcantly
higher in Europe than in the U.S. (RER, 1.37; 95%
conﬁdence interval [95% CI], 1.25–1.50) (Table 3,
Model 1). The excess risk for women age  40 years
was signiﬁcantly higher than for women ages 70–99
years (RER, 1.61; 95% CI, 1.36–1.91). The overall excess
TABLE 1
Number of Cases and Distribution by Stage of Disease at Diagnosis and Age: Women Diagnosed with Breast Carcinoma, 1990–1992,
in SEER and EUROCARE Series
Stage at
diagnosis
SEER EUROCARE
No. of
cases
Age at diagnosis (yrs) (%)
No. of
cases
Age at diagnosis (yrs) (%)
All ages 15–39 40–49 50–69 70–99 All ages 15–39 40–49 50–69 70–99
T1N0M0 5369 40.8 28.7 35.5 43.5 42.7 1293 28.9 29.0 33.4 30.1 23.7
T2–3N0M0 2523 19.2 21.2 20.2 18.4 19.1 831 18.6 16.6 18.2 17.8 20.6
T1–3NM0 3217 24.4 36.1 31.4 24.5 18.1 1389 31.0 39.5 33.5 32.9 24.1
T4 M0 740 5.6 5.1 5.0 4.9 6.9 304 6.8 3.7 4.0 6.0 10.7
M1 783 5.9 5.0 5.3 6.0 6.4 279 6.2 3.4 4.8 6.1 8.1
Not available 540 4.1 3.9 2.6 2.7 6.8 382 8.5 7.8 6.1 7.1 12.8
13,172 100.0 100.0 100.0 100.0 100.0 4478 100.0 100.0 100.0 100.0 100.0
SEER: Surveillance, Epidemiology, and End Results program; EUROCARE: European Concerted Action on Survival and Care of Cancer Patients.
TABLE 2
Number of Women Who Underwent Surgery and Axillary
Lymphadenectomy and Distribution by Number of Lymph Nodes
Evaluated during Lymphadenectomy: Women Diagnosed with Breast
Carcinoma, 1990–1992, in SEER and EUROCARE Series
Characteristics
SEER EUROCARE
No. of cases
(%)
No. of cases
(%)
Surgery 12,788 (97.1) 4040 (90.2)
Lymphadenectomy 10,790 (81.9) 3629 (81.0)
No. of lymph nodes evaluated
1–9 1589 (14.7) 1215 (33.5)
10–14 3170 (29.4) 1120 (30.9)
15 5473 (50.7) 1009 (27.8)
Not available 558 (5.2) 285 (7.8)
Total 10,790 (100.0) 3629 (100.0)
SEER: Surveillance, Epidemiology, and End Results program; EUROCARE: European Concerted Action
on Survival and Care of Cancer Patients.
FIGURE 1. Five-year relative survival rate by stage. Women diagnosed with
breast carcinoma between 1990 and 1992 in the Surveillance, Epidemiology,
and End Results (SEER) program and European Concerted Action on Survival
and Care of Cancer Patients (EUROCARE) series.
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risk was reduced to 1.20 (95% CI, 1.09–1.31) by adjust-
ment for surgery (Model 2). As would be expected,
women treated surgically had a much lower hazard
of death than the minority who did not undergo
surgery (RER, 0.10; 95% CI, 0.09–0.11) and the RER
for each age group was higher after this adjustment.
After inclusion of stage of disease at diagnosis
(Model 3), the overall risk for European women
decreased to 1.12 (95% CI, 1.03–1.22) and the age-
speciﬁc excess risks were smaller than with adjust-
ment for surgery alone. Tumor stage at diagnosis
was found to be strongly and signiﬁcantly associ-
ated with prognosis. With respect to the reference
category of early tumors (T1N0M0), the RER in-
creased from 4.87 to 48.35 for progressively more
advanced disease. For women with breast carci-
noma of unknown stage, the risk was 12.55-fold.
Adjustment for the number of lymph nodes eval-
uated to determine stage (Model 4) further reduced
the excess risk of death among the European women,
which was no longer signiﬁcantly higher than that for
U.S. women (RER, 1.07; 95% CI, 0.98–1.17). Age-spe-
ciﬁc risks were unchanged by this adjustment, but the
RER decreased slightly in most categories of stage.
Women who underwent excision of 15 lymph nodes
were found to have a slightly lower risk than women
with  10 lymph nodes evaluated, whereas women
who did not undergo lymphadenectomy, or for whom
the number of lymph nodes evaluated was not avail-
able, had a signiﬁcantly high risk (RER, 1.80; 95% CI,
1.54–2.11).
The addition of adjuvant radiotherapy (performed
or not) to the last model did not appear to change the
level or signiﬁcance of the excess risk for European
women (RER, 1.08; 95% CI, 0.99–1.18) and the excess
risks for other factors changed very little. Excess risks
were similar among women who were irradiated (RER,
0.93; 95% CI, 0.86–1.02) and those not irradiated (ref-
erence group), or those for whom the information was
not available (RER, 1.04; 95% CI, 0.38–2.87). The in-
teractions between stage and follow-up and stage and
age were found to be individually signiﬁcant, but their
inclusion in the model only slightly altered the excess
risks for European women or the goodness of ﬁt of the
model. Results were omitted from Table 3 for simplic-
ity (they are available on request).
TABLE 3
RER of Death by Age, Disease Stage, and Treatment: 17,650 Women Diagnosed with Breast Carcinoma, 1990–1992,
in SEER and EUROCARE Series
Characteristics No. of women
Model 1 Model 2 Model 3 Model 4
RER 95% CI RER 95% CI RER 95% CI RER 95% CI
Region
SEER 13,172 1 1 1 1
EUROCARE 4478 1.37 1.25–1.50 1.20 1.09–1.31 1.12 1.03–1.22 1.07 0.98–1.17
Age (yrs)
15–39 1238 1.61 1.36–1.91 1.86 1.58–2.18 1.38 1.19–1.60 1.37 1.18–1.59
40–49 3136 1.06 0.91–1.24 1.16 1.01–1.34 0.88 0.78–1.00 0.88 0.78–1.00
50–69 7723 1.10 0.96–1.26 1.24 1.10–1.41 0.98 0.89–1.09 0.98 0.89–1.09
70–99 5553 1 1 1 1
Surgery
No 1211 1 1 1
Yes 16,439 0.10 0.09–0.11 0.38 0.34–0.43 0.53 0.46–0.59
Stage
T1N0M0 6662 1 1
T2–3N0M0 3354 4.87 3.67–6.47 4.54 3.45–5.96
T1–3NM0 4606 10.44 8.03–13.58 10.54 8.20–13.54
T4M0 1044 17.22 13.03–22.76 14.91 11.39–19.51
M1 1062 48.35 36.88–63.38 35.16 26.98–45.81
Not available 922 12.55 9.33–16.88 8.49 6.34–11.38
Evaluated lymph nodes
1–9 2977 1
10–14 4302 0.92 0.79–1.08
15 6509 0.88 0.76–1.02
Not available 3862 1.80 1.54–2.11
RER: relative excess risks; SEER: Surveillance, Epidemiology, and End Results program; EUROCARE: European Concerted Action on Survival and Care of Cancer Patients; CI: 95% conﬁdence interval.
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DISCUSSION
The current study indicates that the higher survival of
women diagnosed with breast carcinoma in 1990 in
areas of the U.S. covered by the SEER program com-
pared with women in the 17 European countries or
regions participating in the EUROCARE study was at-
tributable mainly to differences in disease stage at
diagnosis. Proper adjustment for surgery, stage, and
the adequacy of staging investigations accounted for
much of the difference in risk of death between the
two population-based case series. Tumors were diag-
nosed earlier in the U.S. than in Europe. Even among
the early (T1) tumors, a higher proportion of U.S.
women had small tumors ( 6 mm greatest dimen-
sion; T1a) compared with European women. These
tumors are often diagnosed when asymptomatic,
which suggests more intensive early diagnosis and
detection of asymptomatic tumors in the U.S. than in
Europe.
Adjustment of the RER for age, surgery, stage, and
the number of lymph nodes evaluated greatly reduced
the differences between Europe and the U.S..
The study design did not allow us to distinguish
how much of the difference in survival between the
European and U.S. case series is due to lead time and
how much to postponement of death. However, most
studies of breast carcinoma screening have shown
that diagnosis at an earlier stage is associated with
reduced mortality.13–17
The higher proportion of early tumors among U.S.
women age 65 years helps to explain the ﬁnding that
age appears to bear little relation to prognosis in the
U.S., whereas survival decreases sharply with increas-
ing age at diagnosis in Europe.1 Survival differences
between the U.S. and European series in the current
study data were conﬁned to elderly women.
Survival for all stages of disease was higher for
women in the U.S. than in Europe (Fig. 1). At ﬁrst
glance this might suggest that breast cancer treatment
in the U.S. is more effective than in Europe. However,
the average number of axillary nodes examined was
higher in the U.S. series, indicating a more thorough
search for occult metastasis. The node-negative cate-
gory in Europe may therefore have included a higher
proportion of misclassiﬁed tumors, which were in fact
node-positive, than in the U.S. The fewer nodes exam-
ined, the higher the probability of misclassifying some
node-positive tumors as node-negative: note that the
practice of sentinel node sampling was not wide-
spread in 1990. Inclusion of the number of nodes
examined in the model improved the adjustment for
stage of the relative excess risks, and the relative ex-
cess risk of death in Europe was no longer signiﬁcantly
higher than in the U.S. The improved adjustment is
reﬂected by the fact that women with 15 axillary
nodes examined have a smaller relative excess risk
than women for whom fewer nodes were examined.
Within a given stage category, a higher number of
nodes examined implies a less advanced tumor. Un-
fortunately, we do not have information on bone, liver
or lung scans performed, but the higher survival in the
U.S. of both locally advanced cases and cases with
distant metastasis might reﬂect a more thorough di-
agnostic examination in U.S. women. Only women for
whom data regarding stage were not available had
higher survival in the European series. Women who
did not undergo accurate diagnostic workup are more
likely to have been included in this group in the U.S.
data than in the European data. Unstaged cases in the
European series had survival similar to the overall
overage, suggesting that this group was broadly rep-
resentative of all patients, and that stage was more
often unavailable in Europe simply because the infor-
mation was missing from the clinical records.
Adjustment of the RER for stage was improved
by the inclusion of the number of lymph nodes
evaluated. When many lymph nodes were evaluated
pathologically, cases classiﬁed as lymph node neg-
ative are less likely to be truly lymph node positive
and some cases classiﬁed as lymph node positive
will have only minor lymph node involvement. This
improved adjustment is reﬂected by a smaller ex-
cess risk for cases with  15 lymph nodes evaluated
and a slight increase in the excess risk for the lymph
node-positive category, whereas other stage-speciﬁc
risks decreased.
Nearly all women underwent surgery. Those who
did not were most likely deemed unlikely to beneﬁt
from surgery because their tumor stage was too ad-
vanced. Surgical intervention therefore may be con-
sidered a proxy for stage of disease. Inclusion of sur-
gery in the model had the effect of a crude adjustment
for stage.
After full adjustment for stage, the residual excess
risk of death in the ﬁnal model for European versus
U.S. women was small (7%) and was not statistically
signiﬁcant. Such a small difference might well depend
on residual misclassiﬁcation of tumor stage or staging
procedures. This small excess risk, if real, could also be
attributable to differences in adjuvant therapy. How-
ever, inclusion of information on radiotherapy did not
appear to change the estimated excess risk for women
in Europe. More detailed information concerning the
type and dose of adjuvant radiotherapy, chemother-
apy, and hormone therapy is needed to explore this
issue.
We have considered Europe and the U.S. in these
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analyses as two homogeneous regions, to provide a
broad overview of breast carcinoma survival between
the two continents. However, the SEER program and
the EUROCARE project cover only 10% and 14%, re-
spectively, of the general population in the countries
involved,18 which may not be entirely representative
of the corresponding national populations. The na-
tional life tables used for the U.S. may not reﬂect the
background mortality in contributing areas as closely
as in the European series. The difference in breast
carcinoma survival between the European and U.S.
series may, in part, be due to the particular regions
included. However, this cannot be the only explana-
tion because survival in 22 European countries or
regions for which comparable data are available is
reported to be lower than in any of the U.S. areas
covered by the SEER program.18 The CONCORD study
may further elucidate these differences.1
In Europe, large differences in survival for breast
carcinoma have been observed.2–4,18–20 European ar-
eas with both high and low survival were represented
in the current study. The overall 5-year relative sur-
vival rate ranged from 74% to 82% in France, Italy, and
The Netherlands and from 66% to 76% in Spain, Es-
tonia, and the U.K. These differences were attributable
to differences in stage at diagnosis and treatment.6
European regions with low survival contributed ap-
proximately 50% of the total number of women in the
European component of the current study. The inclu-
sion of other European countries with high breast
carcinoma survival rates (e.g., Sweden, Iceland, Nor-
way, and Finland)19,20 would have reduced further the
residual excess risk of death in Europe.
Breast carcinoma survival rates vary less widely
between the SEER registry areas than between the
countries contributing to EUROCARE. Socioeconomic
status (SES) inﬂuences survival rates in both the U.S.
and Europe,21–23 but we did not include this factor
because comparable data were not available. Breast
carcinoma survival differences in the U.S. are related
to race and SES.24–26 Differences in outcome have also
been reported by type of healthcare delivery.27–29 The
type of health insurance also inﬂuences survival
rates.30 However, the inclusion of European countries
with a wide range of breast carcinoma survival rates
may reﬂect to some extent the range of social and
racial factors inﬂuencing cancer survival rates in the
U.S..
The results of the current study suggest that most
differences in breast carcinoma survival rates between
Europe and the U.S. can be explained by earlier diag-
noses in the U.S.. The results suggest that more re-
sources should be invested to achieve earlier diagnosis
of breast carcinoma in Europe, especially for elderly
women.
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